Nuclear Receptor ROR-Gamma Market
Nuclear Receptor ROR-Gamma Market Scope:
Industry Analysis, Market Size, Growth, Trends Till
2031
Request Sample Report
Nuclear Receptor ROR-Gamma Market Size and Growth
The Nuclear Receptor ROR-Gamma market is witnessing significant growth, driven by rising demand in drug discovery and therapeutic applications. The market size is projected to reach USD 1.2 billion by 2026, fueled by advancements in biomolecular research and increasing investments in immunological therapies, highlighting its vital role in the pharmaceutical sector. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ 4SC AG
◍ Advinus Therapeutics Ltd.
◍ Arrien Pharmaceuticals, LLC
The Nuclear Receptor ROR-Gamma market includes companies like 4SC AG and Biogen, focusing on RORGamma modulators for various diseases. These firms drive market growth through innovative therapies and collaborations. Sales revenues include Biogen: $7.4 billion, Bristol-Myers Squibb: $46.4 billion, and GSK: $43 billion, enhancing market dynamics.
◍ Aurigene Discovery Technologies Limited
◍ Biogen, Inc.
◍ Brickell Biotech, Inc.
◍ Bristol-Myers Squibb Company
◍ Celgene Corporation
◍ Genentech, Inc.
◍ Genfit SA
◍ GlaxoSmithKline Plc
◍ Hanmi Pharmaceuticals, Co. Ltd.
◍ Karo Bio AB
◍ Lead Pharma Holding B.V.
◍ Nuevolution AB
◍ Phenex Pharmaceuticals AG
◍ Reata Pharmaceuticals, Inc.
◍ Teijin Pharma Limited
Request Sample Report
Market Segmentation
By Application
Hospital
Clinic
Others
By Product
◍ VPR-66
INV-17
GSK-2981278
BBI-6000
Others
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
